Anil Ranganath Sells 864 Shares of TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Anil Ranganath sold 864 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. The trade was a 6.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded down $0.34 on Wednesday, hitting $147.66. The company had a trading volume of 701,764 shares, compared to its average volume of 830,019. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. The company has a market cap of $5.06 billion, a PE ratio of 30.13 and a beta of 1.98. TransMedics Group, Inc. has a 52-week low of $62.07 and a 52-week high of $156.00. The business has a 50 day moving average of $134.97 and a 200 day moving average of $126.78.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of TMDX. Vanguard Group Inc. raised its stake in shares of TransMedics Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock valued at $404,549,000 after purchasing an additional 9,650 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after buying an additional 322,353 shares during the period. Geode Capital Management LLC lifted its holdings in TransMedics Group by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock worth $99,339,000 after buying an additional 2,903 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after buying an additional 223,409 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TMDX. JPMorgan Chase & Co. boosted their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Needham & Company LLC boosted their price target on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Piper Sandler increased their price target on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Oppenheimer raised their price objective on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Canaccord Genuity Group upped their target price on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.67.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.